Celladon prices upsized IPO at $8

By
A A A

Celladon Corporation, which is developing a first-in-class gene therapy for patients with systolic heart failure, raised $44 million by offering 5.5 million shares (up from 5.0 million) at $8, as expected. Celladon Corporation plans to list on the NASDAQ under the symbol CLDN. Celladon Corporation initially filed confidentially on 9/6/2013. Barclays acted as the sole bookrunner on the deal.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: CLDN

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Stocks

Referenced

Most Active by Volume

57,500,773
  • $10.50 ▼ 3.14%
50,271,771
  • $17.18 ▲ 0.35%
45,695,436
  • $118.625 ▲ 1.85%
36,407,930
  • $34.70 ▼ 1.64%
33,917,140
  • $47.59 ▼ 0.81%
32,961,221
  • $36.25 ▲ 1.85%
32,213,015
  • $15.67 ▲ 1.56%
29,124,034
  • $30.22 ▼ 0.76%
As of 11/24/2014, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com